Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models.
Kodandaram Pillarisetti, Danlin Yang, Leopoldo Luistro...
https://pubmed.ncbi.nlm.nih.gov/41100731/Actively Recruiting
Led by Janssen Research & Development, LLC · Updated on 2026-11-03
180
Participants Needed
29
Research Sites
186 weeks
Total Duration
Researchers are studying JNJ-79635322, a trispecific antibody, in people with relapsed or refractory multiple myeloma or those previously treated for Amyloid Light-chain AL Amyloidosis. The study aims to find the safest dose and schedule of JNJ-79635322 in a first-in-human phase 1 trial. It also evaluates the safety and tolerability of the drug at the recommended dose among different disease subgroups. Participants receive JNJ-79635322 through subcutaneous injections. The study has two parts Part 1 involves dose escalation to find the recommended phase 2 dose, and Part 2 involves dose expansion where participants receive the drug at the determined dose. The dosing is adjusted sequentially during Part 1 to identify the best regimen for further evaluation. During the study, participants are monitored closely for side effects, including dose-limiting toxicities and adverse events, for up to 2 years and 5 months. Researchers also measure laboratory values, drug levels in the blood, and the presence of anti-drug antibodies. The study assesses preliminary anticancer activity using established response criteria for multiple myeloma and AL amyloidosis. Participants are followed throughout to evaluate safety, tolerability, and treatment responses.
CONDITIONS
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
S
Study Contact
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Janssen Research & Development, LLC
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | JNJ-79635322 (Single-Arm Trial) | Current Standard Regimens (Clinical Guideline Context) |
|---|---|---|
| What is it? | An investigational trispecific antibody targeting BCMA, GPRC5D, and CD3, administered subcutaneously in escalating and expansion doses for patients with relapsed or refractory multiple myeloma or previously treated AL amyloidosis. | Established regimens using agents such as lenalidomide, pomalidomide, proteasome inhibitors (bortezomib, carfilzomib), anti-CD38 monoclonal antibody (daratumumab) for relapsed/refractory myeloma; for AL amyloidosis, therapies include proteasome inhibitors, immunomodulatory agents, alkylators, and anti-CD38 antibody, following international guidelines. |
| Role in trial | Primary investigational intervention in a single-arm, sequential dose escalation and expansion trial. | Not randomized within the trial; serves as external clinical context for patients with relapsed/refractory disease. |
| Primary use or intent | To evaluate safety, dosing, pharmacokinetics, immunogenicity, and preliminary anticancer activity of JNJ-79635322 in patients with advanced myeloma or AL amyloidosis after prior therapies. | To induce clinical response, support remission, and prolong survival using established regimens in patients with similar advanced disease. |
| How is it given or performed? | Subcutaneous injection of JNJ-79635322; dosing schedule escalated in Part 1, expanded in Part 2. Dosing frequency follows trial protocol. | Combination or sequential use of oral, subcutaneous, or intravenous agents as per clinical guideline and treating physician decision. Dosing and schedule tailored to individual response, toxicity, and prior drug exposure. |
| Evidence and maturity | Ongoing clinical investigation; published preclinical data supports target engagement, but efficacy and safety in patients are currently under study in trial and not yet established. | Therapeutic regimens are established as effective for inducing remission, prolonging survival, and managing symptoms in relapsed/refractory multiple myeloma and previously treated amyloidosis; supported by randomized trials and guideline consensus. |
| Important limitations | Limited to heavily pretreated patients; investigational status means long-term safety and clinical benefit are not yet established. Dose escalation/expansion design may not predict risks at all future dose levels. | Efficacy may be limited by cumulative drug resistance and toxicity in heavily pretreated patients; organ involvement in amyloidosis may restrict treatment choices and increase risk. Tolerance of therapy depends on prior exposure and comorbidities. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 2 years 5 months
Participants receive escalating doses of JNJ-79635322 via subcutaneous injection to identify the recommended phase 2 dose.
Duration - Up to 2 years 5 months
Participants receive JNJ-79635322 at the determined recommended dose to assess safety and tolerability in disease subgroups.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Kodandaram Pillarisetti, Danlin Yang, Leopoldo Luistro...
https://pubmed.ncbi.nlm.nih.gov/41100731/Janssen Research & Development, LLC
Lead Sponsor